The global Febuxostat market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Febuxostat, a xanthine oxidase inhibitor, was approved by the FDA in 2009 for the long-term treatment of hyperuricemia in gout patients. Febuxostat drug is a medication that is used to treat gout by reducing uric acid levels. Due […]
